CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2

January 22, 2024 at 02:31 am EST

Copenhagen, Denmark, January 22, 2024 - Cessatech A/S ("Cessatech" or the "Company") announces that all members of the Company's Senior Management and Board of Directors, including CEO Jes Trygved and Chairman of the Board of Directors, Martin Olin, have exercised all their warrants of Series TO2. In totality, Cessatech's Senior Management and Board of Directors will subscribe for approximately DKK 1.75 million through the exercise of their TO2 warrants.

If all the warrants of series TO2 are exercised, the Company will receive approximately DKK 18.1 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than January 26, 2024 or sell the warrants no later than January 24, 2024. Please observe that certain nominees might close their applications earlier than January 26, 2024.

Summarised terms for the warrants of series TO2

Exercise period: January 12, 2024 - January 26, 2024.

Issue size: 3,838,110 warrants of series TO2, which entitles to subscription of 3,838,110 shares. If all the
warrants are exercised, the Company will receive approximately DKK 18.1 million before issuing costs.

Exercise price: DKK 4.71 per share.

Last day trading warrants: January 24, 2024.

Dilution: If all warrants of series TO2 are exercised the share capital will increase with DKK 767,622 from DKK 2,757,751 to DKK 3,525,373. The dilution at the exercise of all warrants of series TO2 amounts to approximately 21.8 percent of the number of shares and number of votes.

Note that the warrants of series T02 that are not exercised on January 26, 2024 at the latest or sold on January 24, 2024 at the latest, will expire without value. For the warrants of series T02 not to expire without compensation, the holder must actively subscribe for new shares or sell the warrants of series T02.

How warrants are exercised

Nominee-registered warrants (Custody account) - Subscription and payment by the exercise of warrants of series T02 shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information. This should be done well before January 26, 2024, as different nominees have different processing times.

Directly-registered warrants (Securities account) - No issue report nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form found on the Company's website.

The warrants of series T02 will then be replaced by interim shares awaiting registration at the Danish Business Authority.

Advisors
Translution Capital acts as financial advisors to the Company in connection with the warrant exercise. Nordic Issuing is the Company's issuing agent whereas Elmann Law Firm is the Company's legal advisor in connection with the warrant exercise of series T02.

This press release constitutes inside information that Cessatech A/S is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.

https://news.cision.com/cessatech/r/cessatech-announces-that-management-and-board-have-exercised-all-their-warrants-of-series-to2,c3912878

https://mb.cision.com/Main/19921/3912878/2552814.pdf

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.62 ^DKK	+1.85%		+5.08%	-8.82%

Feb. 29	Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	23-10-25	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	23-09-21	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	23-09-12	MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	23-09-12	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001	23-08-17	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	23-06-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-29	CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board	23-03-23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Cessatech to Raise $2 Million in Rights Offer	22-11-14	MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	22-09-23	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	22-09-05	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	22-06-30	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	22-05-16	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Cessatech A/S Announces Board Changes	22-03-17	CI
Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001	22-03-08	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI

Cessatech A/S

Equities

CESSA

DK0061411964

CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2

Latest news about Cessatech A/S

Chart Cessatech A/S

Company Profile

Income Statement Evolution